Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Allergy, Atopic Dermatitis, Allergy Medicine +8

Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Larisa J. Geskin, Sara Viragova, Donna B. Stolz et al. · Blood · 2015 · 155 citations · Full text

Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study

Iraj Hasan, Lauren Parsons, Sabrina Duran et al. · Journal of the American Academy of Dermatology · 2024 · 61 citations

Autoimmune Disease, Allergy, Atopic Dermatitis +10

Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis

Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker et al. · JAMA Dermatology · 2023 · 50 citations · Full text